[Clinical Significance of Ipilimumab and the Combination Therapy as Immune Checkpoint Inhibitor].
Ipilimumab is the%ldquo;first in class"immune checkpoint inhibitors, which blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)to potentiate an anti-tumor effect of effector Tcells. Recently, the combination therapy with ipilimumab and anti- PD-1 antibody showed clinical benefit in some malignant tumors, advanced melanoma and renal cell cancer and so on. In this paper, we described clinical development of ipilimumab as the combination therapy including effectiveness and safety.